Current Opinion in Obstetrics and Gynecology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of obstetrics and gynecology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Jonathan S. Berek
Dr Berek is a Professor at Stanford, where he is the Chair of the Department of Obstetrics and Gynecology, the Chief of Obstetrics and Gynecology at the Stanford University Hospital and Clinics, and the Director of the Women's Cancer Center at the Stanford Cancer Center.
Dr Berek is well known as a Professor, Researcher, Author, Editor, Educator, Physician, and Gynecologic Oncologist. He is highly regarded for his research on the clinical management of gynecologic cancers and translational research related to these malignancies. He has published over 500 research papers, book chapters and monographs. He is especially noted for his popular books, Berek & Hacker's Gynecologic Oncology, and Berek & Novak's Gynecology.
Dr Berek earned his undergraduate degree from Brown, his doctor of medicine degree at Johns Hopkins University School of Medicine, completed his residency at Harvard Medical School, the Brigham and Women's Hospital, and his fellowship in gynecologic oncology at the UCLA School of Medicine. For many years, he was a Professor at UCLA, where he was also the Chair of the College of Applied Anatomy.
Dr Berek is the Group Chair and Principal Investigator for the Cooperative Ovarian Cancer Group (COGI). He was a Principal Investigator for the Gynecologic Oncology Group (GOG) for two decades. His primary research interest is in the immunology and immunotherapy of ovarian cancer, and through the development of experimental models and clinical trials, his initial studies encouraged the development of innovative biologic therapy strategies. Through collaborative work, his group focuses on the development of vaccines, monoclonal antibodies and targeted therapies for ovarian cancer. Dr Berek has had grant support from the National Institute of Health (NIH) and the Ovarian Cancer Research Foundation (OCRF).
He is the recipient of the prestigious Sherman Mellinkoff Award and the Excellence in Education Award by the David Geffen School of Medicine at UCLA, and the 2010 John C. Fremont Pathfinder Award. He is regularly listed among America's Best Doctors for Gynecology & Gynecologic Oncology.
He is board certified by the American Board of Obstetrics and Gynecology (ABOG), and the Division of Gynecologic Oncology. He is a Fellow in the American College of Obstetricians and Gynecologists (FACOG) and in the American College of Surgeons (FACS). Dr Berek has served as an examiner for the American Board Obstetrics and Gynecology (ABOG) and for the Council on Resident Education in Obstetrics and Gynecology (CREOG).
Dr Berek is the Immediate Past President of the International Gynecologic Cancer Society (IGCS), and the President-Elect of the Council of University Chairs of Obstetrics and Gynecology (CUCOG). His many honors include receiving the President's Award from the Society of Gynecologic Oncologists (SGO), serving as its Vice President in 1996–1997, and presenting numerous distinguished lectureships. Dr Berek has served on many national committees for the National Institutes of Health, the National Cancer Institute, the American College of Surgeons, the Society of Gynecologic Oncologists, the American College of Obstetricians and Gynecologists (ACOG), and the American Society of Clinical Oncology (ASCO). He is a member of the Society of Gynecologic Investigation (SGI) and the Society of Pelvic Surgeons (SPS).
He is an Editor of Prolog and Précis for the American College of Obstetrics and Gynecology. He is the Editor in Chief of Current Problems in Obstetrics and Gynecology, ASCO News & Forum, and was a Senior Editor of the International Journal of Gynecologic Cancer. He has served on the editorial boards of the Journal of Clinical Oncology, Gynecologic Oncology, and the Journal of the Society for Gynecologic Investigation. He serves as a reviewer for many prestigious journals, including the New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Cancer, and Journal of the National Cancer Institute, among others.
Anne O. Rodriguez
Dr Rodriguez received her medical and undergraduate degrees with honors at Northwestern University and completed her residency in Obstetrics and Gynecology at the University of North Carolina at Chapel Hill. She then completed a three year fellowship in Gynecologic Oncology at the University of Miami/ Jackson Memorial Hospital. Since is currently Associate Professor of Obstetrics and Gynecology at the University of California, Davis, School of Medicine and also maintains an active clinical practice in gynecologic oncology, with a special interest in fertility preservation in cancer patients. She is the program Director for the UCDavis fellowship in gynecologic oncology and is active in multiple research endeavors. She has a special interest in complementary medicine and is trained in medical acupuncture.
Dr Helena Chang received her Ph.D. in Immunology and Microbiology from Temple University in 1975 and took advanced fellowship training in studying the regulatory mechanisms controlling cancer growth.
Her rigorous training in cancer research also led her to realize the importance of combining the research technologies with medical knowledge to advance cancer treatment. She devoted the next decade to completing an M.D., resident training in surgery and fellowship training in surgical oncology from Memorial Sloan-Kettering Cancer Center. She is one of the nation's most distinguished cancer surgeons.
In 1997, she was appointed to the position of Director of the Revlon/UCLA Breast Center. Today, her vision of combining science and practice has been implemented to foster constant advancement in breast cancer diagnosis, treatment and prevention.
Dr Chang's research has focused on the following two areas: to identify breast cancer biomarkers through proteomic analysis for early detection and tailored drug treatment, and to conduct neoadjuvant therapy clinical trials to introduce the most effective systemic therapies into managing various types of breast cancer.
© 2011 Lippincott Williams & Wilkins, Inc.